Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. (NYSE American: IGC) is a clinical-stage biotechnology company whose news flow centers on Alzheimer's disease drug development, pharmaceutical cannabinoids, and AI-enabled research. The company regularly reports updates on its lead asset, IGC-AD1, a cannabinoid-based therapy in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia, along with progress across its broader pipeline and AI platforms.
News about IGC Pharma often includes clinical trial milestones, such as enrollment progress and expansion of the CALMA study to new sites. For example, the company has highlighted reaching key enrollment thresholds and adding hybrid and virtual clinical sites like Dominion Medical Associates, part of Lightship's network, to improve access for patients in underserved and rural communities. These announcements provide insight into trial design, recruitment strategies, and geographic reach.
Investors and observers can also expect corporate and financial updates, including capital raises under an effective Form S-3 shelf registration statement, strategic divestitures of non-core assets, and changes to the company's fiscal year-end to align with the calendar year. SEC-reported events, such as registered direct offerings and asset sale closings, are frequently accompanied by press releases that explain how proceeds and transactions relate to IGC Pharma's clinical and research priorities.
Another recurring theme in IGC Pharma's news is AI and intellectual property developments. The company reports advances in its MINT-AD platform for Alzheimer's risk stratification and early detection, recognition from the National Institute on Aging for AI code quality, and new or allowed patents that expand its pharmaceutical cannabinoid portfolio, including microdose-based treatments for stuttering and Tourette's Syndrome.
In addition, IGC Pharma issues news on community and educational initiatives, such as sponsoring a caregiver-focused Alzheimer's book authored by neuropsychology experts. Together, these news items provide a view into the company's clinical progress, AI research, regulatory positioning, capital strategy, and engagement with the Alzheimer's community. Readers interested in IGC's stock and operations can use this news feed to follow trial updates, financing events, patent activity, and strategic decisions over time.
India Globalization Capital reported Q3 results for the fiscal year 2022. The Company appointed James Moran to its Board of Directors, enhancing its expertise in healthcare. It completed a Phase 1 clinical trial for IGC-AD1, aimed at treating Alzheimer’s disease, showing promising results in reducing Neuropsychiatric Symptoms. The Life Sciences segment generated $134 thousand in revenue, while the Infrastructure segment brought in $8 thousand. The net loss was approximately $2.38 million, or ($0.05) per share. R&D expenses rose to $377 thousand, reflecting increased clinical trial activities.
India Globalization Capital, Inc. (IGC) has appointed former Congressman Jim Moran as an independent Director on its Board. With 24 years in Congress, Moran is known for his bipartisan leadership and focus on healthcare, environment, and defense. He will provide valuable insights as IGC advances its Phase 2/3 trials of the THC-based investigational drug for Alzheimer’s disease. Moran's experience in innovative research could strengthen IGC’s initiatives in cannabinoid-based therapies, aiming for FDA-approved clinical trials.
India Globalization Capital (IGC) announced positive results from its Phase 1 clinical trial for IGC-AD1, a cannabinoid-based drug for Alzheimer's disease. The primary endpoint focused on safety and tolerability was successfully met, with minimal adverse events reported. The trial involved 36 elderly patients who showed no serious safety concerns. The company plans to advance the trial to assess efficacy, pending FDA approval. IGC aims to improve the quality of life for Alzheimer's patients through further testing of IGC-AD1.
India Globalization Capital, Inc. (IGC) has announced preliminary results from its Phase 1 clinical trial for IGC-AD1, a cannabis-based drug candidate for Alzheimer’s disease. Key insights into pharmacokinetics and genotyping have been obtained, crucial for determining optimal dosing in future trials pending FDA approval. The trial showed mean Tmax values of 2.15 hours for THC and 1.9 hours for OH-THC, and mean T1/2 values of 3.60 hours for THC and 3.30 hours for OH-THC, suggesting safe dosing frequencies. Further trials are planned to establish the drug's safety and efficacy.
India Globalization Capital, Inc. (IGC) announced preliminary positive findings from its Phase 1 clinical trial for IGC-AD1, a THC-based drug aimed at treating Alzheimer’s symptoms. The trial highlighted significant decreases in anxiety (50-60%) and agitation (35-60%) among participants. The results were shared in a Clinical/Statistical Report filed with the FDA. IGC plans to expand the study with a placebo-controlled trial pending FDA approval. Alzheimer's affects 50 million globally, with no approved medications for symptom relief, underscoring the potential impact of IGC-AD1.
India Globalization Capital, Inc. (NYSE American: IGC) reported financial results for Q2 of fiscal 2022, ending September 30, 2021. Revenue declined to approximately $56,000 from $125,000 in the same quarter last year, with Infrastructure segment revenue at $3,000 down from $67,000. SG&A expenses surged to about $4.1 million due to inventory theft and legal costs. R&D expenses increased slightly to $276,000 and the net loss widened to approximately $4.3 million or ($0.08) per share. The company is progressing with the Phase 1 trial of its THC-based drug IGC-AD1 for Alzheimer’s, expecting future FDA submissions.
India Globalization Capital, Inc. (IGC) held its Annual Meeting of Shareholders on October 15, 2021, where all voting matters in the Definitive Proxy filed with the SEC were approved.
Key approvals included:
- Election of Richard Prins to the board until 2024.
- Ratification of Manohar Chowdhry & Associates as the independent accounting firm for fiscal year 2022.
- Granting 3,500,000 shares to employees and consultants based on performance metrics.
- Proposal to adjourn the meeting if necessary to solicit more proxy votes.
India Globalization Capital (IGC) has completed its Phase 1 clinical trial of IGC-AD1, a cannabis-based investigational drug for Alzheimer’s disease. The trial involved 12 participants, primarily elderly individuals with mild to moderate Alzheimer’s. Results indicate that IGC-AD1 was safe and well-tolerated. Secondary endpoints have also been completed, but results are yet to be disclosed. IGC plans to seek FDA concurrence on these findings and aims for future trials to support potential relief for the projected 50 million Alzheimer’s patients worldwide by 2030.
India Globalization Capital, Inc. (IGC) reported financial results for Q2 2021, revealing revenues of approximately $77,000, down from $584,000 in Q2 2020. The decline is attributed to COVID-19's impact, particularly in its Infrastructure segment. Notably, IGC received a patent for its Alzheimer’s treatment, IGC-AD1, and completed its Phase 1 clinical trial. R&D expenses rose to about $444,000 due to the trial, while the company recorded a net loss of $1.8 million, slightly improved from $1.9 million a year earlier. Liquidity remains adequate for upcoming efficacy trials.
India Globalization Capital (IGC) announced the issuance of a patent (#11,065,225) by the USPTO for the treatment of Alzheimer’s disease using an ultra-low dose of THC. The patent stems from research initiated by the University of South Florida and was licensed exclusively to IGC in 2017. IGC's proprietary formulation, IGC-AD1, is currently undergoing Phase 1 clinical trials to assess its safety and tolerability. The release also highlights potential risks and uncertainties related to commercialization and FDA approval.
FAQ
What is the current stock price of IGC Pharma (IGC)?
What is the market cap of IGC Pharma (IGC)?
